

## STENTYS revenues for the first half of 2012 increase 92% over prior year

Princeton, New Jersey and Paris, France, July 25 2012 - STENTYS (NYSE Euronext, FR0010949404 – STNT), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), today reports its unaudited revenues for the half year ending 30 June 2012.

- **Revenues for the first half and the second quarter represent robust growth over prior year**

€ thousands	Half year – 6 months			Quarter – 3 months		
	H1 2012	H1 2011	Var %	Q2 2012	Q2 2011	Var %
<b>Revenues</b>	<b>1,149.6</b>	599.0	+91.9%	<b>655.6</b>	347.6	+88.6%

In line with growing use of STENTYS stents in hospitals in the 8 European countries where they are being premarketed, revenues for the second quarter of 2012 grew substantially, totaling €655.6 thousand compared to €347.6 thousand for the second quarter of 2011, an increase of 88.6%.

For the first half of 2012, revenues totaled €1,149.6 thousand, compared to €599.0 thousand for the first half of 2011, an increase of 91.9%.

- **Cash position: solid balance sheet**

STENTYS had a net cash position of €16.7 million at 30 June 2012.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, concludes: "*STENTYS recorded a strong first half for 2012: continued sales growth, launch of the new Stentys AC aspiration catheter, and impressive clinical results from our APPOSITION III trial. During the second half of the year, we anticipate further sales growth and a possible FDA clearance to begin clinical trials in the United States.*"

- **Upcoming financial results**

Financial statements for the first half of 2012 are expected to be published on 31 August 2012, before market opening.

### About STENTYS:

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS has commenced marketing activities of its flagship product in several European countries. Its Self-Apposing Stent® adapts to the anatomic changes of the artery in the post-infarction phase and thus prevents the malapposition problems associated with conventional stents. STENTYS Self-Apposing® stent showed very low mortality at one month in 1,000 high risk heart attack patients in the APPOSITION III study . More information is available at [www.stentys.com](http://www.stentys.com)

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

**STENTYS**

Stanislas Piot

CFO

Tel.: +33 (0)1 44 53 99 42

[stan.p@stentys.com](mailto:stan.p@stentys.com)**Investor & Press Relations****Europe: NewCap.**

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

[stentys@newcap.fr](mailto:stentys@newcap.fr)**US: MacDougall Biomedical Communications**

Kari Watson, Tel.: +1 781 235 3060

Christine Labaree, Tel.: +1 650 339 7533

[stentys@macbiocom.com](mailto:stentys@macbiocom.com)

STENTYS is listed on Compartment C of the NYSE Euronext Paris  
ISIN: FR0010949404 – Ticker: STNT